Advanced Proteome Therapeutics
The company appears to have an online presence at https://advancedproteome.com, but the account is currently suspended, and no additional information about its mission or vision is available from the provided content.
Industries
Nr. of Employees
small (1-50)
Patents
Crosslinking of proteins and other entities via conjugates of α-haloacetophenones, benzyl halides, quinones, and their derivatives
US-9770515-B2
View DetailsSite-specific labeling and targeted delivery of proteins for the treatment of cancer
US-9545449-B2
View DetailsSite-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
US-8927485-B2
View DetailsTandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
US-7927579-B2
View Details
Crosslinking of proteins and other entities via conjugates of α-haloacetophenones, benzyl halides, quinones, and their derivatives
US-9770515-B2
View DetailsSite-specific labeling and targeted delivery of proteins for the treatment of cancer
US-9545449-B2
View DetailsSite-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
US-8927485-B2
View DetailsTandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
US-7927579-B2
View DetailsProducts
Universal Antibody Connectors (UAC)
A platform technology for creating uniform and homogenous antibody-drug conjugates (ADCs) by using proprietary site-selective chemistries for protein modification.
Antibody-Drug Conjugates (ADCs)
Therapeutic agents that combine antibodies with cytotoxic drugs to target and kill cancer cells while sparing healthy cells.
Antibody Radioisotope Conjugates (ARCs)
Therapeutic agents that combine antibodies with radioisotopes for targeted cancer treatment, leveraging the UAC technology.
SARS-CoV-2 Protease Inhibitor Program
A research initiative focused on developing therapeutic candidates against SARS-CoV-2, the virus causing COVID-19.
Universal Antibody Connectors (UAC)
A platform technology for creating uniform and homogenous antibody-drug conjugates (ADCs) by using proprietary site-selective chemistries for protein modification.
Antibody-Drug Conjugates (ADCs)
Therapeutic agents that combine antibodies with cytotoxic drugs to target and kill cancer cells while sparing healthy cells.
Antibody Radioisotope Conjugates (ARCs)
Therapeutic agents that combine antibodies with radioisotopes for targeted cancer treatment, leveraging the UAC technology.
SARS-CoV-2 Protease Inhibitor Program
A research initiative focused on developing therapeutic candidates against SARS-CoV-2, the virus causing COVID-19.